The U.S. Congress greenlit a historic $315 million in federal ALS research funding for 2026 amid Rare Disease Month, spotlighting biotech progress like VectorY Therapeutics' first patient dosing in ...
ALS Association yearly report cards show no U.S. state earned the highest score for policies supporting patients; several had ...
The first patient has been dosed in a Phase 1/2 clinical study of VTx-002, an experimental therapy for amyotrophic lateral sclerosis.
Getting older is one of the biggest risks for these progressive diseases that degrade functions of the brain, the spine and ...
Allowing people with disabilities to talk by just thinking about a word, that's what UC Davis researchers hope to accomplish with new cutting-edge technology. It can be a breakthrough for people with ...
COUNTY SHERIFF’S DEPARTMENT. WELL, IMAGINE HAVING A MEDICINE HELPING TO KEEP YOU ALIVE AND SUDDENLY IT IS GONE. WE’RE HEARING FROM A WOMAN LIVING WITH ALS OR LOU GEHRIG’S DISEASE, WHO SAYS SHE MAY BE ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Researchers have found that patients with amyotrophic lateral sclerosis have ...
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo in ALS patients, which is carried to the CNS, where it binds to and damages neurons ...
A simple non-invasive hair-based test could one day help with early diagnosis of amyotrophic lateral sclerosis (ALS)—improving patient care and potentially extending survival. This is the hope of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results